Study on the use of Koselugo for treating Neurofibromatosis 1

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the safety and effectiveness of Koselugo (Selumetinib) in patients with Neurofibromatosis 1, specifically focusing on those treated in routine clinical practice settings in South Korea. It is part of a post-approval commitment by the Korean health authority to gather real-world data on the drug's performance. The study will assess known safety profiles and identify any previously unknown adverse reactions while providing insights into the treatment outcomes for the Korean patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
2. Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion Criteria:

1. Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
2. Provision of signed and dated written informed consent by the patient or legally acceptable representative

Where it's running

• Research Site
  Busan, South Korea Recruiting
• Research Site
  Chungcheongbuk-do, South Korea Recruiting
• Research Site
  Daejeon, South Korea Recruiting
• Research Site
  Gyeonggi-do, South Korea Recruiting
• Research Site
  Incheon, South Korea Recruiting
• Research Site
  Jeonnam, South Korea Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing PAS-004 for adults with Neurofibromatosis Type 1 and plexiform neurofibromas

  This study is testing a new medication called PAS-004 to see if it is safe and helps adults with Neurofibromatosis Type 1 and painful plexiform neurofibromas.

  Recruiting at 5 sites Phase 1 Pasithea Therapeutics Corp. · Birmingham, Alabama and 4 other locations · NCT06961565

• Combination therapy to shrink plexiform neurofibromas in NF1 patients

  This trial tests whether the drugs cabozantinib and selumetinib can be safely given together to see if they help shrink progressive or painful plexiform neurofibromas in adolescents and adults with NF1.

  Recruiting at 8 sites Phase 1 University of Alabama at Birmingham · Birmingham, Alabama and 7 other locations · NCT06502171

• Early selumetinib to try to prevent plexiform neurofibromas in young children with NF1

  This trial will see if giving selumetinib to young children with NF1 who are at high risk can prevent or slow the development of plexiform neurofibromas.

  Recruiting at 15 sites Phase 2 University of Alabama at Birmingham · Birmingham, Alabama and 14 other locations · NCT06188741

• Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

  This registry-following study tests how well and safely selumetinib works in adults with NF1 who have symptomatic, inoperable PN.

  Recruiting AstraZeneca · Beijing and 25 other locations · NCT07888517

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• Online program providing personalized NF1 care letters plus videos or peer navigator support for adults with low health literacy

  This study will test whether giving adults with NF1 and low health literacy personalized care letters plus either short, plain-language videos or a call with a trained peer navigator helps them better understand NF1 symptoms and care before their primary care visit.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07233408

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.